These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21870888)

  • 1. Role of serotonin in Alzheimer's disease: a new therapeutic target?
    Geldenhuys WJ; Van der Schyf CJ
    CNS Drugs; 2011 Sep; 25(9):765-81. PubMed ID: 21870888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.
    Joshi A; Wang DH; Watterson S; McClean PL; Behera CK; Sharp T; Wong-Lin K
    Neuropharmacology; 2020 Sep; 174():108118. PubMed ID: 32380022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The serotonin 5-HT4 receptor and the amyloid precursor protein processing.
    Lezoualc'h F; Robert SJ
    Exp Gerontol; 2003; 38(1-2):159-66. PubMed ID: 12543273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin: A New Hope in Alzheimer's Disease?
    Claeysen S; Bockaert J; Giannoni P
    ACS Chem Neurosci; 2015 Jul; 6(7):940-3. PubMed ID: 26011650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research.
    Jankowska A; Wesolowska A; Pawlowski M; Chlon-Rzepa G
    Curr Med Chem; 2018; 25(17):2045-2067. PubMed ID: 28554324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease.
    Werner FM; Covenas R
    Curr Pharm Des; 2016; 22(14):2064-71. PubMed ID: 26818863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
    Hajjo R; Setola V; Roth BL; Tropsha A
    J Med Chem; 2012 Jun; 55(12):5704-19. PubMed ID: 22537153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating 5-HT
    Lalut J; Karila D; Dallemagne P; Rochais C
    Future Med Chem; 2017 May; 9(8):781-795. PubMed ID: 28504917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triquinane-based compounds as possible serotonin 5-HT(6) receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Med Hypotheses; 2007; 68(1):81-6. PubMed ID: 16962723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance.
    Bali A; Singh S
    Curr Top Med Chem; 2015; 15(17):1643-62. PubMed ID: 25915615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.
    Ramirez MJ; Lai MK; Tordera RM; Francis PT
    Drugs; 2014 May; 74(7):729-36. PubMed ID: 24802806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT(6) receptor and cognition.
    Codony X; Vela JM; Ramírez MJ
    Curr Opin Pharmacol; 2011 Feb; 11(1):94-100. PubMed ID: 21330210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.